We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bayer’s Nubeqa Improves Overall Survival in Metastatic Prostate Cancer
Bayer’s Nubeqa Improves Overall Survival in Metastatic Prostate Cancer
Bayer’s phase 3 study of Nubeqa (darolutamide) in combination with androgen-deprivation therapy (ADT) and docetaxel for patients with metastatic hormone-sensitive prostate cancer has hit its primary endpoint, showing that the combo improved overall survival compared to docetaxel and ADT alone.